JP2004501608A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004501608A5 JP2004501608A5 JP2001568372A JP2001568372A JP2004501608A5 JP 2004501608 A5 JP2004501608 A5 JP 2004501608A5 JP 2001568372 A JP2001568372 A JP 2001568372A JP 2001568372 A JP2001568372 A JP 2001568372A JP 2004501608 A5 JP2004501608 A5 JP 2004501608A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- protein
- activity
- vegf
- gene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000765 processed proteins & peptides Proteins 0.000 description 36
- 229920001184 polypeptide Polymers 0.000 description 34
- 102000004196 processed proteins & peptides Human genes 0.000 description 34
- 108090000623 proteins and genes Proteins 0.000 description 32
- 238000000034 method Methods 0.000 description 31
- 230000000694 effects Effects 0.000 description 23
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 21
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 21
- 239000003814 drug Substances 0.000 description 19
- 230000001105 regulatory effect Effects 0.000 description 18
- 101710155665 Mesencephalic astrocyte-derived neurotrophic factor Proteins 0.000 description 14
- 102100021833 Mesencephalic astrocyte-derived neurotrophic factor Human genes 0.000 description 14
- 206010028980 Neoplasm Diseases 0.000 description 13
- 101710137189 Amyloid-beta A4 protein Proteins 0.000 description 12
- 101710151993 Amyloid-beta precursor protein Proteins 0.000 description 12
- 102100022704 Amyloid-beta precursor protein Human genes 0.000 description 12
- 102100021506 NADH-ubiquinone oxidoreductase chain 4 Human genes 0.000 description 12
- 101710106576 NADH-ubiquinone oxidoreductase chain 4 Proteins 0.000 description 12
- DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 description 12
- 102000055046 tissue-factor-pathway inhibitor 2 Human genes 0.000 description 12
- 108010016054 tissue-factor-pathway inhibitor 2 Proteins 0.000 description 12
- 101001076680 Homo sapiens Insulin-induced gene 1 protein Proteins 0.000 description 11
- 102100025887 Insulin-induced gene 1 protein Human genes 0.000 description 11
- 101710106575 NADH-ubiquinone oxidoreductase chain 1 Proteins 0.000 description 11
- 102100038625 NADH-ubiquinone oxidoreductase chain 1 Human genes 0.000 description 11
- -1 hVPS41p Proteins 0.000 description 11
- 102100027557 Calcipressin-1 Human genes 0.000 description 10
- 101000580357 Homo sapiens Calcipressin-1 Proteins 0.000 description 10
- 102100033824 A-kinase anchor protein 12 Human genes 0.000 description 9
- 102100030878 Cytochrome c oxidase subunit 1 Human genes 0.000 description 9
- 102100037567 Dual specificity protein phosphatase 14 Human genes 0.000 description 9
- 101000779382 Homo sapiens A-kinase anchor protein 12 Proteins 0.000 description 9
- 101000919849 Homo sapiens Cytochrome c oxidase subunit 1 Proteins 0.000 description 9
- 101000881116 Homo sapiens Dual specificity protein phosphatase 14 Proteins 0.000 description 9
- 101000806511 Homo sapiens Protein DEPP1 Proteins 0.000 description 9
- 102100037469 Protein DEPP1 Human genes 0.000 description 9
- 102100037415 Regulator of G-protein signaling 3 Human genes 0.000 description 9
- 101710140411 Regulator of G-protein signaling 3 Proteins 0.000 description 9
- 239000003795 chemical substances by application Substances 0.000 description 9
- 101000601048 Homo sapiens Nidogen-2 Proteins 0.000 description 8
- 102100037371 Nidogen-2 Human genes 0.000 description 8
- 201000011510 cancer Diseases 0.000 description 7
- 102000040430 polynucleotide Human genes 0.000 description 7
- 108091033319 polynucleotide Proteins 0.000 description 7
- 239000002157 polynucleotide Substances 0.000 description 7
- 230000001225 therapeutic effect Effects 0.000 description 7
- 108010039419 Connective Tissue Growth Factor Proteins 0.000 description 6
- 102000015225 Connective Tissue Growth Factor Human genes 0.000 description 6
- 102100033299 Glia-derived nexin Human genes 0.000 description 6
- 101800001649 Heparin-binding EGF-like growth factor Proteins 0.000 description 6
- 101000997803 Homo sapiens Glia-derived nexin Proteins 0.000 description 6
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 6
- 102100033762 Proheparin-binding EGF-like growth factor Human genes 0.000 description 6
- 230000033115 angiogenesis Effects 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 239000000523 sample Substances 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 108700005075 Regulator Genes Proteins 0.000 description 4
- 239000005557 antagonist Substances 0.000 description 4
- 230000033228 biological regulation Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 201000010374 Down Syndrome Diseases 0.000 description 3
- 108091006027 G proteins Proteins 0.000 description 3
- 102000030782 GTP binding Human genes 0.000 description 3
- 108091000058 GTP-Binding Proteins 0.000 description 3
- 101000921808 Haemophilus influenzae (strain ATCC 51907 / DSM 11121 / KW20 / Rd) Probable cytochrome oxidase subunit 1 Proteins 0.000 description 3
- 101000771974 Homo sapiens Vacuolar protein sorting-associated protein 41 homolog Proteins 0.000 description 3
- 101000668058 Infectious salmon anemia virus (isolate Atlantic salmon/Norway/810/9/99) RNA-directed RNA polymerase catalytic subunit Proteins 0.000 description 3
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 3
- 102100029496 Vacuolar protein sorting-associated protein 41 homolog Human genes 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 229960003387 progesterone Drugs 0.000 description 3
- 239000000186 progesterone Substances 0.000 description 3
- 230000006884 regulation of angiogenesis Effects 0.000 description 3
- 230000011664 signaling Effects 0.000 description 3
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 2
- 108090000312 Calcium Channels Proteins 0.000 description 2
- 102000003922 Calcium Channels Human genes 0.000 description 2
- 201000009030 Carcinoma Diseases 0.000 description 2
- 208000005243 Chondrosarcoma Diseases 0.000 description 2
- 208000007571 Ovarian Epithelial Carcinoma Diseases 0.000 description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 239000012472 biological sample Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 230000003828 downregulation Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 2
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 2
- 201000005249 lung adenocarcinoma Diseases 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- 201000008968 osteosarcoma Diseases 0.000 description 2
- 206010041823 squamous cell carcinoma Diseases 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- 230000003827 upregulation Effects 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 1
- 102100026112 60S acidic ribosomal protein P2 Human genes 0.000 description 1
- 108020004491 Antisense DNA Proteins 0.000 description 1
- 108020005544 Antisense RNA Proteins 0.000 description 1
- 108091023037 Aptamer Proteins 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 108090000994 Catalytic RNA Proteins 0.000 description 1
- 102000053642 Catalytic RNA Human genes 0.000 description 1
- 101000691878 Homo sapiens 60S acidic ribosomal protein P2 Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 108091061763 Triple-stranded DNA Proteins 0.000 description 1
- 206010073104 Tubular breast carcinoma Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 150000001413 amino acids Chemical group 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 239000003816 antisense DNA Substances 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000003184 complementary RNA Substances 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- HSUGRBWQSSZJOP-RTWAWAEBSA-N diltiazem Chemical compound C1=CC(OC)=CC=C1[C@H]1[C@@H](OC(C)=O)C(=O)N(CCN(C)C)C2=CC=CC=C2S1 HSUGRBWQSSZJOP-RTWAWAEBSA-N 0.000 description 1
- 229960004166 diltiazem Drugs 0.000 description 1
- 201000002696 invasive tubular breast carcinoma Diseases 0.000 description 1
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 1
- 229960001597 nifedipine Drugs 0.000 description 1
- 108091008104 nucleic acid aptamers Proteins 0.000 description 1
- 229920000768 polyamine Polymers 0.000 description 1
- 108091092562 ribozyme Proteins 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 230000005748 tumor development Effects 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 229960001722 verapamil Drugs 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US19120100P | 2000-03-21 | 2000-03-21 | |
| PCT/US2001/009043 WO2001070174A2 (en) | 2000-03-21 | 2001-03-21 | Vegf-modulated genes and methods employing them |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2004501608A JP2004501608A (ja) | 2004-01-22 |
| JP2004501608A5 true JP2004501608A5 (enExample) | 2008-05-08 |
Family
ID=22704517
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001568372A Pending JP2004501608A (ja) | 2000-03-21 | 2001-03-21 | Ｖｅｇｆ調節遺伝子及びそれらを利用する方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (3) | US20020132978A1 (enExample) |
| EP (1) | EP1290005A4 (enExample) |
| JP (1) | JP2004501608A (enExample) |
| AU (2) | AU2001250912B2 (enExample) |
| CA (1) | CA2403804A1 (enExample) |
| WO (1) | WO2001070174A2 (enExample) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2001278746A1 (en) * | 2000-08-16 | 2002-02-25 | Chugai Seiyaku Kabushiki Kaisha | Seamless soft capsule preparations containing dihydrobenzofuran derivatives |
| DE60238038D1 (de) * | 2001-03-20 | 2010-12-02 | Cns Protein Therapeutics Inc | Das Überleben dopaminerger Neuronen fördernde Faktoren und deren Verwendungen |
| US7452969B2 (en) | 2002-08-30 | 2008-11-18 | Licentia Ltd | Neurotrophic factor protein and uses thereof |
| EP1644406B1 (en) | 2003-07-11 | 2012-08-15 | DeveloGen Aktiengesellschaft | Use of dg153 secreted protein products for preventing and treating pancreatic diseases and/or obesity and/or metabolic syndrome |
| WO2005082412A1 (ja) * | 2004-02-26 | 2005-09-09 | Perseus Proteomics Inc. | 癌の治療および予防薬 |
| WO2005094888A1 (ja) | 2004-03-31 | 2005-10-13 | Two Cells Co. Ltd. | 損傷組織の治療剤と治療方法 |
| MX2007010922A (es) * | 2005-03-10 | 2007-10-12 | Genentech Inc | Metodos y composiciones para modular la integridad vascular. |
| PL1969003T3 (pl) | 2005-12-14 | 2011-05-31 | Herantis Pharma Plc | Zastosowanie białka czynnika neurotroficznego |
| WO2009120810A2 (en) * | 2008-03-25 | 2009-10-01 | Cns Protein Therapeutics, Inc. | Neurodegenerative disorders |
| JP5337868B2 (ja) | 2008-04-23 | 2013-11-06 | ノヴァセル テクノロジー インコーポレイテッド． | 血管新生ペプチド |
| FI20080326A0 (fi) | 2008-04-30 | 2008-04-30 | Licentia Oy | Neurotroofinen tekijä MANF ja sen käytöt |
| CA2730068A1 (en) | 2008-07-07 | 2010-01-14 | Oxford Nanopore Technologies Limited | Base-detecting pore |
| US20110229877A1 (en) | 2008-07-07 | 2011-09-22 | Oxford Nanopore Technologies Limited | Enzyme-pore constructs |
| US9132168B2 (en) | 2008-08-05 | 2015-09-15 | University Of South Florida | Methods of treating cognitive impairment |
| CN102215860A (zh) * | 2008-08-05 | 2011-10-12 | 南佛罗里达大学 | 治疗认知损害的方法 |
| EP2312896B1 (en) | 2008-08-06 | 2018-01-10 | Sharp Kabushiki Kaisha | Base station device, mobile station device and corresponding communication methods using carrier aggregation |
| GB0820927D0 (en) | 2008-11-14 | 2008-12-24 | Isis Innovation | Method |
| EP2391732B1 (en) | 2009-01-30 | 2015-05-27 | Oxford Nanopore Technologies Limited | Methods using adaptors for nucleic acid constructs in transmembrane sequencing |
| CN102482330A (zh) * | 2009-01-30 | 2012-05-30 | 牛津纳米孔技术有限公司 | 酶突变体 |
| GB0905140D0 (en) | 2009-03-25 | 2009-05-06 | Isis Innovation | Method |
| WO2012094600A1 (en) * | 2011-01-06 | 2012-07-12 | William Marsh Rice University | Methods for treating lysosomal storage diseases using l-type ca2+ channel blockers with a 1,4 dihydropyridine structure and inhibitors of er-associated degradation |
| BR112013020411B1 (pt) | 2011-02-11 | 2021-09-08 | Oxford Nanopore Technologies Limited | Monômero de msp mutante, construto, polinucleotídeo, poro, kit e aparelho para caracterizar uma sequência de ácido nucleico alvo, e, método para caracterizar uma sequência de ácido nucleico alvo |
| CA2838818A1 (en) * | 2011-06-09 | 2012-12-13 | University Of Miami | Methods of treatment for retinal diseases |
| KR20140050067A (ko) | 2011-07-25 | 2014-04-28 | 옥스포드 나노포어 테크놀로지즈 리미티드 | 막횡단 포어를 사용한 이중 가닥 폴리뉴클레오티드 서열분석을 위한 헤어핀 루프 방법 |
| WO2013153359A1 (en) | 2012-04-10 | 2013-10-17 | Oxford Nanopore Technologies Limited | Mutant lysenin pores |
| US11155860B2 (en) | 2012-07-19 | 2021-10-26 | Oxford Nanopore Technologies Ltd. | SSB method |
| GB201314695D0 (en) | 2013-08-16 | 2013-10-02 | Oxford Nanopore Tech Ltd | Method |
| CA2901545C (en) | 2013-03-08 | 2019-10-08 | Oxford Nanopore Technologies Limited | Use of spacer elements in a nucleic acid to control movement of a helicase |
| GB201313477D0 (en) | 2013-07-29 | 2013-09-11 | Univ Leuven Kath | Nanopore biosensors for detection of proteins and nucleic acids |
| GB201403096D0 (en) | 2014-02-21 | 2014-04-09 | Oxford Nanopore Tech Ltd | Sample preparation method |
| US10443097B2 (en) | 2014-05-02 | 2019-10-15 | Oxford Nanopore Technologies Ltd. | Method of improving the movement of a target polynucleotide with respect to a transmembrane pore |
| CN119899249A (zh) | 2014-09-01 | 2025-04-29 | 弗拉芒区生物技术研究所 | 突变csgg孔 |
| US10266885B2 (en) | 2014-10-07 | 2019-04-23 | Oxford Nanopore Technologies Ltd. | Mutant pores |
| GB201418159D0 (en) | 2014-10-14 | 2014-11-26 | Oxford Nanopore Tech Ltd | Method |
| GB201609220D0 (en) | 2016-05-25 | 2016-07-06 | Oxford Nanopore Tech Ltd | Method |
| US11254738B2 (en) * | 2016-09-07 | 2022-02-22 | The Governing Council Of The University Of Toronto Banting Institute | Synthetic antibodies against VEGF and their uses |
| EP3774858B1 (en) * | 2018-03-29 | 2025-07-30 | MyNeuroCure Oy | C-terminal cdnf fragments having neuroprotective effect |
| GB201807793D0 (en) | 2018-05-14 | 2018-06-27 | Oxford Nanopore Tech Ltd | Method |
| EP3814492A4 (en) | 2018-06-29 | 2022-02-23 | Wuhan Neurophth Biotechnology Limited Company | Compositions and methods for treating leber's hereditary optic neuropathy |
| KR20210068014A (ko) * | 2018-08-20 | 2021-06-08 | 우한 뉴로프스 바이오테크놀로지 리미티드 컴퍼니 | 레버 유전성 시신경병증의 치료를 위한 조성물 및 방법 |
| CN113025633B (zh) | 2019-12-09 | 2024-08-27 | 武汉纽福斯生物科技有限公司 | 编码人nadh脱氢酶亚单位1蛋白的核酸及其应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AT374041B (de) * | 1982-03-25 | 1984-03-12 | Naimer H L | Stern-dreieck-schalter mit nullspannungsausloesung |
| US4758195A (en) * | 1986-09-08 | 1988-07-19 | 3 W Designers, Inc. | Elastomeric foam building units |
| FR2626254B1 (fr) * | 1988-01-27 | 1990-07-06 | Valois Sa | Poussoir-etui avec systeme de garantie |
| US5174392A (en) * | 1991-11-21 | 1992-12-29 | Reinhardt Paul A | Mechanically actuated fluid control device for downhole fluid motor |
| US5455338A (en) * | 1993-11-05 | 1995-10-03 | Zymogenetics, Inc. | DNA encoding novel human kunitz-type inhibitors and methods relating thereto |
| DE4340891A1 (de) * | 1993-12-01 | 1995-06-08 | Mahle Gmbh | Hubkolben für Verbrennungsmotoren aus insbesondere Leichtmetall |
| US5856103A (en) * | 1994-10-07 | 1999-01-05 | Board Of Regents The University Of Texas | Method for selectively ranking sequences for antisense targeting |
| US6410046B1 (en) * | 1996-11-19 | 2002-06-25 | Intrabrain International Nv | Administering pharmaceuticals to the mammalian central nervous system |
| WO2001019851A2 (en) * | 1999-09-16 | 2001-03-22 | Neurotrophic Bioscience Inc. | Opaminergic neuronal survival-promoting factors and uses thereof |
| EP1225224A4 (en) * | 1999-10-01 | 2004-03-24 | Kyowa Hakko Kogyo Kk | DNA THE SHEAR RESPONSE |
| MX2007010922A (es) * | 2005-03-10 | 2007-10-12 | Genentech Inc | Metodos y composiciones para modular la integridad vascular. |
-
2001
- 2001-03-21 AU AU2001250912A patent/AU2001250912B2/en not_active Expired
- 2001-03-21 WO PCT/US2001/009043 patent/WO2001070174A2/en not_active Ceased
- 2001-03-21 JP JP2001568372A patent/JP2004501608A/ja active Pending
- 2001-03-21 EP EP01924240A patent/EP1290005A4/en not_active Withdrawn
- 2001-03-21 US US09/815,153 patent/US20020132978A1/en not_active Abandoned
- 2001-03-21 AU AU5091201A patent/AU5091201A/xx active Pending
- 2001-03-21 CA CA002403804A patent/CA2403804A1/en not_active Abandoned
-
2003
- 2003-05-02 US US10/428,487 patent/US20040006780A1/en not_active Abandoned
-
2007
- 2007-10-31 US US11/932,133 patent/US20080166724A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| El-Tanani et al. | The regulation and role of osteopontin in malignant transformation and cancer | |
| Rebar et al. | Induction of angiogenesis in a mouse model using engineered transcription factors | |
| Adamson et al. | Egr1 transcription factor: multiple roles in prostate tumor cell growth and survival | |
| Perbal | NOV (nephroblastoma overexpressed) and the CCN family of genes: structural and functional issues | |
| Qi et al. | Talin2-mediated traction force drives matrix degradation and cell invasion | |
| Wright et al. | Vaccinia virus late transcription is activated in vitro by cellular heterogeneous nuclear ribonucleoproteins | |
| US20050004017A1 (en) | Methods and compositions for treating hcap associated diseases | |
| WO2003009813A2 (en) | Methods of treating neuropilin-mediated diseases | |
| Kim et al. | Role of alternative splicing of periostin in human bladder carcinogenesis | |
| CA2266325A1 (en) | A family of genes encoding apoptosis-related peptides, peptides encoded thereby and methods of use thereof | |
| JP2002534995A5 (enExample) | ||
| Jiang et al. | A novel transcriptional regulatory region within the core promoter of the hepatocyte growth factor gene is responsible for its inducibility by cytokines via the C/EBP family of transcription factors | |
| Uthoff et al. | VEGF isoforms and mutations in human colorectal cancer | |
| Calovini et al. | Steroid‐hormone regulation of myosin subunit expression in smooth and cardiac muscle | |
| KR20120051258A (ko) | Ｇｋｎ １을 함유하는 항암용 조성물 | |
| EP2566965B1 (en) | Antagonists of sema3e/plexind1 interaction as anti-cancer agents | |
| Wu et al. | Secreted frizzled-related proteins in angiogenesis: molecular mechanisms and clinical implications | |
| Nakamura et al. | Neural EGFL like 2 expressed in myoepithelial cells and suppressed breast cancer cell migration | |
| Mori et al. | Identification of brain-specific splicing variants of the hDLG1 gene and altered splicing in neuroblastoma cell lines | |
| JP2002518016A5 (enExample) | ||
| WO2011076095A1 (en) | Methods and compositions related to reduced met phosphorylation by leukocyte cell-derived chemotaxin 2 in tumor cells | |
| Bianco et al. | Detection and localization of Cripto‐1 binding in mouse mammary epithelial cells and in the mouse mammary gland using an immunoglobulin–cripto‐1 fusion protein | |
| JP4834677B2 (ja) | Ｃｃｎ３によるｃｃｎ２の調節ならびに線維症、硬化症および他の疾患におけるその治療的可能性ならびに診断的可能性 | |
| CA3007055C (en) | Camkk1 as a novel regenerative therapeutic | |
| CA2446197A1 (en) | Use of alpha 1-antichymotrypsin polypeptides, or nucleic acids encoding them, or of a cell which is expressing an act polypeptide, or a nucleic acid encoding it, for treatment and/or prevention of diabetes-associated and/or arterial poorly healing wounds and for identifying pharmacologically active substances |